These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 30951841

  • 1. Unrelated Donor Peripheral Blood Stem Cell Transplantation for Patients with β-Thalassemia Major Based on a Novel Conditioning Regimen.
    Sun L, Wang N, Chen Y, Tang L, Xing C, Lu N, Shi Y, Ma Y, Lin F, Yu K, Feng J.
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1592-1596. PubMed ID: 30951841
    [Abstract] [Full Text] [Related]

  • 2. A novel conditioning regimen improves outcomes in β-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation.
    Li C, Wu X, Feng X, He Y, Liu H, Pei F, Liao J, He L, Shi L, Li N, Liu Q, Liu S, Chen G, Su Q, Ren Y, Wang Y, Tan W.
    Blood; 2012 Nov 08; 120(19):3875-81. PubMed ID: 22968457
    [Abstract] [Full Text] [Related]

  • 3. Modified conditioning regimen improves outcomes of unrelated donor peripheral blood stem cell transplantation for β-thalassaemia major patients.
    Huang K, Zhou DH, Li Y, Xu HG, Que LP, Chen C, Xue HM, Guo HX, Weng WJ, Huang SL, Fang JP.
    Pediatr Blood Cancer; 2018 Jul 08; 65(7):e27026. PubMed ID: 29512932
    [Abstract] [Full Text] [Related]

  • 4. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH, Lee JH, Lee JH, Kim DY, Park HS, Choi EJ, Ko SH, Seol M, Lee YS, Kang YA, Jeon M, Baek S, Kang YL, Kim SH, Yun SC, Kim H, Jo JC, Choi Y, Joo YD, Lim SN.
    Biol Blood Marrow Transplant; 2017 Sep 08; 23(9):1555-1566. PubMed ID: 28552421
    [Abstract] [Full Text] [Related]

  • 5. Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major.
    Hussein AA, Al-Zaben A, Ghatasheh L, Natsheh A, Hammada T, Abdel-Rahman F, Abu-Jazar H, Sharma S, Najjar R, Frangoul H.
    Pediatr Blood Cancer; 2013 Aug 08; 60(8):1345-9. PubMed ID: 23424175
    [Abstract] [Full Text] [Related]

  • 6. Haploidentical haematopoietic stem cell transplantation for thalassaemia major based on an FBCA conditioning regimen.
    Sun Q, Wu B, Lan H, Meng F, Ma X, Chen X, Huang Z, Yao Q, Xu J, Huang Y, Wu S, Zhu Z.
    Br J Haematol; 2018 Aug 08; 182(4):554-558. PubMed ID: 29962035
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
    Ji YS, Lee MS, Min CW, Park SK, Kim SH, Yun J, Kim HJ, Kim KH, Kim CK, Lee KT, Won JH, Hong DS.
    Korean J Intern Med; 2016 Jul 08; 31(4):750-61. PubMed ID: 27017944
    [Abstract] [Full Text] [Related]

  • 9. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
    Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE.
    Biol Blood Marrow Transplant; 2015 May 08; 21(5):906-12. PubMed ID: 25667989
    [Abstract] [Full Text] [Related]

  • 10. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR.
    Bone Marrow Transplant; 2001 Oct 08; 28(7):643-7. PubMed ID: 11704786
    [Abstract] [Full Text] [Related]

  • 11. Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.
    Kharbanda S, Smith AR, Hutchinson SK, McKenna DH, Ball JB, Lamb LS, Agarwal R, Weinberg KI, Wagner JE.
    Biol Blood Marrow Transplant; 2014 Apr 08; 20(4):581-6. PubMed ID: 24370862
    [Abstract] [Full Text] [Related]

  • 12. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.
    Bredeson CN, Zhang MJ, Agovi MA, Bacigalupo A, Bahlis NJ, Ballen K, Brown C, Chaudhry MA, Horowitz MM, Kurian S, Quinlan D, Muehlenbien CE, Russell JA, Savoie L, Rizzo JD, Stewart DA.
    Biol Blood Marrow Transplant; 2008 Sep 08; 14(9):993-1003. PubMed ID: 18721762
    [Abstract] [Full Text] [Related]

  • 13. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major.
    Ghavamzadeh A, Iravani M, Ashouri A, Mousavi SA, Mahdavi N, Shamshiri A, Hadjibabaie M, Namdar R, Nedaeifard L, Ghaffari H, Alimoghaddam K.
    Biol Blood Marrow Transplant; 2008 Mar 08; 14(3):301-8. PubMed ID: 18275896
    [Abstract] [Full Text] [Related]

  • 14. The Saudi experience in fludarabine-based conditioning regimens in patients with Fanconi anemia undergoing stem cell transplantation: excellent outcome in recipients of matched related stem cells but not in recipients of unrelated cord blood stem cells.
    Ayas M, Al-Seraihi A, El-Solh H, Al-Ahmari A, Khairy A, Aldali A, Markiz S, Siddiqui K, Al-Jefri A.
    Biol Blood Marrow Transplant; 2012 Apr 08; 18(4):627-32. PubMed ID: 21871862
    [Abstract] [Full Text] [Related]

  • 15. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
    Choudhary D, Sharma SK, Gupta N, Kharya G, Pavecha P, Handoo A, Setia R, Katewa S.
    Biol Blood Marrow Transplant; 2013 Mar 08; 19(3):492-5. PubMed ID: 23160007
    [Abstract] [Full Text] [Related]

  • 16. Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen.
    Resnick IB, Aker M, Tsirigotis P, Shapira MY, Abdul-Hai A, Bitan M, Gesundheit B, Amar A, Ackerstein A, Samuel S, Slavin S, Or R.
    Bone Marrow Transplant; 2007 Nov 08; 40(10):957-64. PubMed ID: 17846604
    [Abstract] [Full Text] [Related]

  • 17. Effects of two doses of anti-T lymphocyte globulin-Fresenius given after full-match sibling stem cell transplantation in acute myeloblastic leukemia patients who underwent myeloablative fludarabine/busulfan conditioning.
    Boga C, Yeral M, Gereklioglu C, Asma S, Maytalman E, Aytan P, Kozanoglu I, Sariturk C, Ozdogu H.
    Hematol Oncol Stem Cell Ther; 2018 Sep 08; 11(3):149-157. PubMed ID: 29474820
    [Abstract] [Full Text] [Related]

  • 18. French multicenter 22-year experience in stem cell transplantation for beta-thalassemia major: lessons and future directions.
    Galambrun C, Pondarré C, Bertrand Y, Loundou A, Bordigoni P, Frange P, Lutz P, Mialou V, Rubie H, Socié G, Schneider P, Bernaudin F, Paillard C, Michel G, Badens C, Thuret I, French Rare Disease Center for Thalassemia, French Society of Bone Marrow Transplantation.
    Biol Blood Marrow Transplant; 2013 Jan 08; 19(1):62-8. PubMed ID: 22892550
    [Abstract] [Full Text] [Related]

  • 19. Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor.
    Blaise D, Fürst S, Crocchiolo R, El-Cheikh J, Granata A, Harbi S, Bouabdallah R, Devillier R, Bramanti S, Lemarie C, Picard C, Chabannon C, Weiller PJ, Faucher C, Mohty B, Vey N, Castagna L.
    Biol Blood Marrow Transplant; 2016 Jan 08; 22(1):119-24. PubMed ID: 26341397
    [Abstract] [Full Text] [Related]

  • 20. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
    Zaidman I, Rowe JM, Khalil A, Ben-Arush M, Elhasid R.
    Biol Blood Marrow Transplant; 2016 Jun 08; 22(6):1043-1048. PubMed ID: 27016193
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.